Investigations in Immunology: TACI Localization in B Cells by Sanborn, Keri
Persistent link: http://hdl.handle.net/2345/581
This work is posted on eScholarship@BC,
Boston College University Libraries.
Boston College Electronic Thesis or Dissertation, 2006
Copyright is held by the author, with all rights reserved, unless otherwise noted.
Investigations in Immunology: TACI









Investigations in Immunology: 
 























Senior Honors Thesis 
Boston College 
April 28, 2006 
Acknowledgements 
 
I would like to thank my family and friends for supporting me throughout all of 
my college experience, and in particular during the extremely busy process of writing 
my thesis.  Without their love and support, I would probably have spent many hours 
staring at a blank computer screen on more than one occasion during this year.  Their 
support has been an inspiration and has shown me that I can achieve anything I set my 
heart on. 
I would also like to thank Dr. Tom Chiles for his help and advice during my 
thesis-writing process.  His guidance has taught me a lot about science and taught me to 
be self-reliant in my knowledge and my work. 
Abstract 
 
For ten weeks during the summer of 2005, I was a Summer Undergraduate 
Research Fellow in an immunology laboratory at the Mayo Clinic.  My research focused 
on the BLyS/APRIL system and the receptor TACI on the surface of B cells.  Going into 
my summer research, I had very little experience in immunology.  Throughout the 
process of writing this thesis, I have sought to improve upon my knowledge of 
immunology, building a cohesive story that begins with basic biology and ends with the 
results of the summer’s experiments. 
The first part of this thesis covers topics in general immunology, and narrow 
down in focus to cover the function and development of lymphocytes and B cell 
maturation and activation.  In the second part of the thesis, the background for my 
research is described in more detail, and topics such as autoimmunity and cancer, lipid 
rafts, cell polarization, the BLyS/APRIL system for B cell survival, and TACI are covered 
extensively.  The final portion of this thesis discusses the experimental logic, a 
background on materials and methods, and the results of the experiments I conducted 
over the summer.  By reading this thesis, anyone with a background in biology should 
become familiar with basic subjects in immunology, advanced concepts in the study of 
lymphocytes, the ligands BLyS and APRIL, and the receptor TACI in B cells. 
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Preface: Notation 
 
It is important to note that midway through this thesis, there is a shift from using 
textbook-based sources to using scientific papers.  Because of this shift, the notation 
used for citing sources will also change. 
In Part I, as well as the Preface to Part II, textbooks are the primary sources cited.  
In these sections, citation more typical of a humanities paper will be utilized, including 
footnotes and a Works Cited section at the end of the paper.  This method of citation 
enables the reader to find the pages cited in each particular section of the paper. 
In Part II and Part III, papers from scientific journals are the primary sources 
cited.  In these sections, citation commonly used in scientific papers will be used.  This 
includes a parenthetical reference for each citation, as well as a References section in the 
back of the paper. 
This method of citation is intended to reflect the nature of sources used and the 
nature of scientific knowledge which each section is based upon. 
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Introduction: Purpose and Goals 
 
In the summer of 2005, I had the privilege of being a student in the Summer 
Undergraduate Research Fellowship 
program at the Mayo Clinic in Rochester, 
Minnesota.  For ten weeks, I worked full-
time in the lab of Dr. Diane Jelinek, an 
immunologist who primarily concentrates 
on B cells.  To be entirely honest, I wasn’t 
sure I would enjoy myself that summer.  I 
had applied to the Molecular Genetics 
program at Mayo, and instead, with no background or previous interest in immunology, 
I was asked to join the Immunology department instead.  In my mind as I began the 
project, I remembered that it would be only ten weeks of my life, and that even if I didn’t 
enjoy it, it would be a valuable experience.  I began the summer unsure of my interest in 
immunology and even of my decision to pursue a career in research.  What followed was 
possibly one of the best summers of my life.  I left Mayo in August with a newfound 
passion for immunology and a renewed commitment to graduate school and the field of 
scientific research. 
The Jelinek lab, my home and family for the summer.
As I began my summer research project, I had no background in immunology, 
beyond the typical Intro Bio and Molecular Cell Biology courses in college.  I didn’t 
really know the difference between B cells and T cells, or the function of an antibody.  I 
certainly didn’t know anything about the BLyS/APRIL system with which I would 
become very familiar over the next ten weeks.  In research there is a very steep learning 
curve, and I learned the basics of the system I was working on and the techniques 
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necessary for my research very quickly.  What I didn’t have time to learn, due to the 
hectic nature of the summer, was the background behind my research.  Knowing that 
detailed, intricate knowledge is nothing without a foundation to build it upon, I set out 
this year to build that foundation by beginning with the basics.  While my summer 
research project is the inspiration for my thesis, in fact it is the end point of this work. 
The purpose of this thesis is to begin at the beginning.  It is to start with a broad 
understanding of immunology and work 
down to the details surrounding my 
summer research.  As I began with very 
little knowledge of immunology, this 
thesis should provide all of the necessary 
background to bridge the gap from basic 
biology to the intricate details of my 
project, making it possible for anyone 
with a basic background in biology to understand the material in the thesis.  My goal is 
to provide anyone who reads this paper from cover to cover with the knowledge 
necessary to understand all of the intricacies of the BLyS/APRIL system and TACI in B 
cells, as well as the concepts of receptor localization and lipid rafts and how these 
concepts relate to my research. 
Celebrating at the end of the summer.  You should 
feel this good when you finish reading this thesis. 
To anyone who picks up this thesis, I hope you enjoy learning about the world of 
B cells as much as I have enjoyed researching it.  Through this window into a small piece 
of B cell research, perhaps you will come to appreciate the role of TACI in the 
fascinatingly complex system of B cell survival and regulation. 










Part I: Basic B Cell Biology 
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Section I: A Brief Overview of the Human Body’s Defenses 
 
Throughout our lives, we come into contact with many disease-causing viruses 
and bacteria, as well as other environmental pathogens.  When our bodies are faced with 
these invaders, they employ both nonspecific and specific types of defense. 
The body’s nonspecific line of defense is both external and internal.  In order to 
enter the body, a pathogen must first penetrate the physical and chemical barriers of the 
skin or the mucous membrane linings of the respiratory, digestive, and urogenital tracts.  
After these barriers have been surmounted, the pathogen will face many nonspecific 
internal defenses, including various types of phagocytic cells such as macrophages, 
eosinophils, and neutrophils; natural killer (NK) cells; and the many chemicals that 
create an inflammatory response.  These defenses do not distinguish among pathogens, 
but they are often very effective at limiting the scope of an infection or preventing 
infection altogether.  They can also be useful in activating the body’s specific defenses. 
The body’s more specific type of defense is primarily based on lymphocytes, a 
subset of white blood cells which are designed to protect the body against foreign 
invaders.  Lymphocytes, which include several types of B and T cells, are responsible for 
secreting antibodies against specific pathogens and for recognizing and killing infected 
cells.  They are also responsible for protecting the body against cancer by killing cells 
which have become cancerous.  The responses of lymphocytes to a pathogen are specific 
to the pathogen, yet lymphocytes are able to provide an enormous amount of diversity 
because each cell recognizes a different antigen.  Through a system that combines 
specificity with diversity, lymphocytes make it possible for the body to combat virtually 
any pathogen it encounters. 
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While many connections between the body’s two types of defense will be made, 
this thesis will primarily focus on lymphocytes and the body’s more specific defenses 
against pathogens, particularly B lymphocytes and their role in the immune system.1
                                                 
1 Parts of section are summarized from Campbell & Reece, Biology. 
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Section II: The Cells of the Immune System 
 
The body’s specific and non-specific defenses are both provided by leukocytes, or 
white blood cells.  Along with red blood cells, leukocytes arise from hematopoietic stem 
cells in the bone marrow, which mature to form more limited stem cells of many types. 
Hematopoietic stem cells can form the myeloid progenitor, which is the precursor 
cell type for most of the cells that make up the innate (non-specific) immune system.  
The myeloid progenitor gives rise to macrophages, which are phagocytic cells that 
circulate through tissues to engulf invaders; specialized antigen presenting cells called 
dendritic cells; mast cells, which have a key role in allergic responses and may also 
protect the body’s mucosal surfaces; and granulocytes, including neutrophils, 
eosinophils, and basophils, which assist in fighting bacterial and parasitic infections as 
well as stimulating an allergic response. 
The lymphoid progenitor, which also arises from hematopoietic stem cells, is the 
precursor cell type for lymphocytes, the cells which make up the adaptive (specific) 
immune system, as well as natural killer cells 
and some dendritic cells.  Two types of 
lymphocytes exist in the body: T cells and B 
cells.  T cells, which leave the bone marrow to 
complete maturation in the thymus, 
differentiate into both cytotoxic cells, which 
kill infected cells, and helper cells, which 
activate other lymphocytes and macrophages.  B cells, which complete their maturation 
in the bone marrow, differentiate into plasma cells, which secrete antibodies that fight 
A T cell and B cell.  Note the difference between 
the TCR and BCR.  Figure created using 
VisiScience ScienceSlides graphics. 
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foreign molecules in the body, and memory cells, which boost the immune response 
upon a second exposure to an antigen. 
Lymphocytes must encounter an antigen and, in some cases, co-stimulatory 
molecules in order to become activated and differentiate.  Each lymphocyte has 
specificity for a unique antigen, created through the modular design of the genes for the 
T cell receptor (TCR) and B cell receptor (BCR).  While the T cell receptor is always 
membrane-bound, the B cell receptor is a membrane-bound form of the antibody 
molecule, or immunoglobulin (Ig), that is secreted by activated plasma B cells. 
Along with lymphocytes, the lymphoid progenitor also produces natural killer 
(NK) cells.  NK cells are active in the innate immune system and play a key role in 
recognizing abnormal cells in the body such as tumor cells.  Some dendritic cells are also 
produced by the lymphoid progenitor, but these dendritic cells appear identical to those 
produced by the myeloid progenitor, and the majority of the body’s dendritic cells are of 
myeloid origin. 
The cells of the immune system work together, combining innate and adaptive 
immunity in many different ways to effectively fight off pathogens and guard against cell 
abnormalities and cancer.2
                                                 
2 Parts of section summarized from Sompayrac, How the Immune System Works. 
  10 
Section III: Adaptive and Innate Immunity 
 
The first line of defense when the body is invaded by a pathogen is its innate 
immunity.  Innate immunity is relatively nonspecific, designed to target common 
elements of pathogens, such as cell surface molecules.  Because the adaptive immune 
response can take four to seven days to build, the body’s innate response is critical in 
fighting pathogens immediately after they have been introduced into the body, and it 
can even prevent the need for an adaptive response altogether. 3
Immediately upon encountering a pathogen, the cells that provide the body’s 
innate immunity recognize the pathogen as non-self through structures, such as 
unmethylated CpG DNA, that are common to many different antigens.4  The first cells to 
encounter a pathogen are typically the macrophages, which circulate in the blood and 
tissues and engulf foreign molecules through phagocytosis.  When a macrophage comes 
into contact with a surface molecule on a pathogen, it engulfs the invader and begins to 
secrete cytokines and chemokines, which begin the inflammation process.  When the 
infection site becomes inflamed, the blood vessels near the area dilate to allow more 
cells to come into contact with the pathogens, causing redness, pain, heat, and swelling.  
Additionally, the endothelium of the blood vessels becomes more adhesive, causing 
more leukocytes to stick to the endothelium and migrate to the site of infection.  
Inflammation increases the flow of the lymph, which contains antigen presenting cells 
that can become activated by encountering an antigen and go on to activate 
lymphocytes. 
                                                 
3 Janeway, Travers, Walport, & Shlomchik, Immunobiology, 12. 
4 Janeway, 15. 
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Upon secretion of cytokines by macrophages and an increase in the flow of 
lymph, dendritic cells that have been recruited to the site of infection come into contact 
with a pathogen.  In a similar manner to macrophages, the dendritic cells ingest an 
antigen through phagocytosis, causing them to become activated and mature into 
antigen presenting cells (APCs).  They then migrate to the lymph nodes, where they 
present the antigen in order to activate T cells. 
Following the activation of T cells by dendritic cells, the adaptive immune 
response begins to play an active role in fighting the pathogens that are invading the 
body.  Because of the genetic 
mechanism that creates the T cell 
receptor and B cell receptor, each 
lymphocyte recognizes a different 
antigen.  B cells are able to 
recognize free-floating, whole 
antigen molecules, while T cells 
recognize only smaller, 
fragmented peptide antigens 
presented on MHC I or MHC II 
molecules.  When a lymphocyte recognizes its specific antigen, it becomes activated, 
stops migrating, and enlarges.  The activated cell, called a lymphoblast, divides 
approximately four times every 24 hours for 3-5 days.  Through this process, called 
clonal expansion, the lymphoblast produces many cells with the same antigenic 
specificity.  These cells differentiate into their respective effector cells – cytotoxic 
Clonal expansion. 
Image created using VisiScience ScienceSlides program. 
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lymphocytes in the case of T cells, or plasma cells in the case of B cells – and their cell-
adhesion molecules change, allowing them to migrate into tissues to fight infections. 
When T cells and B cells enter infected tissues, they help the body fight against 
pathogens in unique ways.  While cytotoxic lymphocytes, or “killer” T cells, kill infected 
cells by inducing apoptosis, B cells protect the body from free antigen molecules by 
secreting antibodies.  These antibodies mark (opsonize) antigens for ingestion by 
macrophages and prevent bacteria and viruses from entering new cells by blocking their 
receptor-binding sites (neutralization).  In addition, antibodies also activate the 
complement system, which is helpful to the body during bacterial infections.  Through 
the combination of cytotoxic T cells and antibody-secreting B cells, the body is typically 
able to combat pathogens and prevent further infection. 
After an antigen has been eliminated, the effector cells which were generated to 
help fight the infection undergo apoptosis.  A subset of the antigen-specific B cells and T 
cells remain, however, and create the body’s immunological memory.  These cells, 
known as memory cells, persist in larger numbers than naïve lymphocytes and are easier 
to activate, helping the body to quickly fight off a secondary infection with the same 
antigen.  In addition, the secondary antibody response reaches a much higher level than 
the primary response and produces antibodies with a higher affinity to the antigen. 
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Section IV: Lymphocytes 
 
The key players in the adaptive immune response are T cells and B cells, 
collectively known as lymphocytes.  T cells, the lymphocytes that mature in the thymus, 
are activated through a system known as antigen presentation, the process of one cell 
activating another cell by presenting a protein fragment to it.   
Antigen presentation is done via two different molecules, major 
histocompatibility complex (MHC) class I molecules and MHC class II molecules.  MHC 
class I molecules are used by all of the body’s cells to 
display proteins from inside the cell, which have 
traveled through the proteasome to be cleaved into 
fragments small enough to fit into the MHC I 
molecule.  This type of antigen presentation is used to 
show the cytotoxic lymphocytes the internal 
environment of the cell in order to signal the immune 
system to kill infected cells.  In contrast, MHC II 
molecules are used by the cells of the immune system to display proteins brought in 
from the extracellular environment.  Presentation by MHC II molecules tells the 
immune system, in particular helper T cells, that something is wrong in another part of 
the body, causing the activation and proliferation of naive T cells.  Specialized antigen 
presenting cells, particularly dendritic cells, are instrumental in presentation using 
MHC II molecules.  Overall, antigen presentation is an important mechanism to ensure 
that cytotoxic lymphocytes are well regulated, as T cells are only able to recognize an 
antigen if it is properly presented in an MHC molecule. 
Antigen Presentation 
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All T cells have a T cell receptor (TCR), composed of two different proteins, that 
recognizes a specific antigen.  While approximately 5% of the body’s T cells contain a γδ 
receptor and do not express either CD4 or CD8 molecules, the vast majority of T cells 
contains an αβ TCR and express CD4 or CD8 on their cell surface.5  These cells 
recognize a small peptide antigen presented by an MHC molecule on the surface of an 
infected somatic cell or activated immune cell.  Within the two classes of αβ T cells, 
helper T cells express the CD4 molecule and recognize antigen presented on an MHC II 
molecule, and cytotoxic T cells express the CD8 molecule and recognize antigen 
presented on an MHC I molecule.  The CD4 and CD8 molecules act as co-receptors and 
signaling molecules, assisting in antigen recognition and telling the cell which actions to 
take in response to activation. 
Following antigen recognition, the cell’s T cell receptors cluster together, or 
cross-link, to allow the cell to reach the signaling threshold necessary to activate the cell.  
This cross-linking often occurs through signaling platforms in the cell surface called 
lipid rafts, which bring together TCRs and other associated signaling molecules in order 
to generate and amplify a signal.  A T cell activated through its cross-linked TCRs will 
proliferate and upregulate growth factor receptors on its surface.  This activation also 
requires additional co-stimulatory molecules, such as B7 on an antigen-presenting cell. 
CD4+ cells, or helper T cells, help to activate B cells and other T cells by secreting 
cytokines.  A naïve helper T cell (TH0) usually secretes only IL-2, but upon activation, it 
will generally differentiate to secrete one of two subsets of cytokines, depending on the 
signals it receives from dendritic cells.  Although the rules of cytokine secretion do not 
appear to be strict, a TH1 cell usually secretes cytokines such as IL-1, IFN-γ, and tumor 
                                                 
5 Sompayrac, How the Immune System Works, 56. 
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necrosis factor (TNF), while a TH2 cell secretes IL-4, IL-5, and IL-10.6  These signals 
help to activate various cells of the immune system during the fight against a pathogen. 
CD8+ cells, or cytotoxic lymphocytes (CTLs), fight pathogens by killing infected 
cells to stop the spread of the infection.  The activation of CTLs requires antigen 
presentation on an MHC I molecule, as well as signals from a helper T cell.  Upon 
activation, a CTL proliferates, then enters the bloodstream to search for cells infected by 
its cognate antigen, which it will recognize via MHC I.  Using weapons such as perforin, 
which creates holes in the cell membrane, or FasL, which binds to a receptor on the cell 
surface, the T cell induces programmed cell death (apoptosis) in infected cells.  While 
most T cells die within a few days of activation (a phenomenon termed “activation 
induced cell death”), some are kept alive as memory cells and are easily re-activated 
upon a second exposure to the pathogen. 
In contrast to the action-hero profile of T cells, B lymphocytes have a somewhat 
less glamorous existence.  While this means that B cells are not as frequently studied in 
recent studies of the immune system, they are in fact crucial in the fight against some 
pathogens.  B cells, like T cells, originate in the bone marrow, but unlike T cells, they do 
not migrate to another location to complete their maturation.  The B cell contains a B 
cell receptor (BCR) which, much like the TCR, arises from the rearrangement of gene 
segments and is composed of two different proteins.  In the case of the BCR, the 
proteins are the heavy chain (Hc) and light chain (Lc), which come together in a dimer 
of dimers.  The BCR is identical to the antibody which is secreted by the B cell, with the 
exception that the BCR contains a short segment of amino acids which anchors it to the 
cell membrane.  Through the Hc-associated proteins Igα and Igβ, the BCR signals to the 
                                                 
6 Sompayrac, 60-61. 
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cell when it encounters its cognate antigen.  In a similar manner to the TCR, BCRs on 
the surface of B cells cross-link to generate a signal sufficient to begin an enzymatic 
cascade within the cell.  B cells also contain complement receptors, which cross-link 
with the BCR to amplify the signal. 
B cell activation is comprised of two components.  First, the BCR must recognize 
its cognate antigen.  Unlike T cells, which can only recognize properly presented peptide 
antigens, B cells are able to recognize whole antigen molecules by binding to epitopes on 
their surfaces.  While B cells do not require the presentation of antigen on MHC 
molecules, they do require a secondary signal, which can be obtained through numerous 
pathways.  The most common method of secondary activation is T cell dependent 
activation, which requires the interaction of a CD40L molecule on the surface of a T 
helper cell with the CD40 receptor on B cells.  Some cells may be activated without the 
help of a T cell, however, and can undergo T cell independent activation or polyclonal 
activation.  The mechanism of T cell independent response helps the body recognize 
unique molecules on the surface of invaders that would not typically be recognized by T 
cells.  Once a B cell is activated through one of these methods, the cell begins to 
proliferate, but it will not secrete antibodies until it receives a cytokine signal. 
Upon activation, a B cell chooses during maturation to become either a plasma 
cell or a memory cell.  Plasma cells, also called antibody-secreting cells, are generally 
located in the spleen or bone marrow.  From these locations, they secrete antibodies at a 
rate of 2,000 antibodies per second for several days.7  This effort is strenuous, however, 
and plasma cells are typically short-lived, dying after only a few days of secreting 
antibodies.  In contrast to plasma cells, memory cells retain their membrane-bound B 
                                                 
7 Sompayrac, 39. 
  17 
cell receptors and continue to survive in the bloodstream for longer periods of time, 
conferring a quick immune response 
to the organism upon second exposure 
to an antigen.  Due to various genetic 
mechanisms, the secondary response 
to an antigen is faster, stronger, and 
has a higher affinity than the primary 
response.  Memory cells are typically 
formed in immune responses that 
require T cell help. 
As the experiment described in 
the remainder of this thesis involves only B cells, this section is the furthest extent to 
which T cells will be covered.  While T cells are important to the immune response, they 
are not a major component of the experiments performed to study the receptor TACI, 
and as such, they will not be discussed in detail in the rest of this thesis.  The next 
section will describe, in greater detail, the process of B cell maturation and generation of 
diversity. 
The fate of B cells.  Once a cell is activated and 
proliferates, its clones must choose to become plasma cells 
or memory cells. 
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Section V: B Cell Maturation and Mechanisms of B Cell Diversity 
 
B cells begin their existence as hematopoietic stem cells in the bone marrow of an 
organism.  The cell differentiation process takes B cells through a series of stages, each 
of which possesses unique markers.  It should be noted, however, that while some 
surface markers change, after a stem cell becomes a precursor of a B cell, it possesses 
the cell surface marker CD19. 
After a lymphoid progenitor makes the decision to become a B cell (thus 
becoming a committed lymphocyte progenitor), it first becomes a pro-B cell, which 
expresses the molecules B220 and CD43 on its surface.  Following this change, the pro-
B cell becomes a pre-B cell, which expresses B220 on its surface but does not express 
CD43.  The pre-B cell then develops into an immature B cell, which has the surface 
markers B220 and IgM.  While all of the stages up until the immature B cell stage are 
marked by a rearrangement of genes on the B cell receptor, the immature B cell 
possesses a fully rearranged heavy chain and light chain.  Immature B cells further 
develop into mature naïve B cells, which possess the surface markers B220, IgM, and 
IgD.  Mature naïve B cells are similar to effector B cells, but as they have not yet 
encountered antigen, they do not possess all of the characteristics of either plasma or 
memory cells.  It is important to note that upon maturation, mature naïve B cells leave 
the bone marrow and enter the periphery, where they will be activated by encountering 
an antigen for which they have specificity.8
Upon activation, a B cell becomes a lymphoblast and must make a career decision 
to become either a plasma cell or a memory cell.  Memory cells, which express B220, 
MHCII, IgG, and IgA, lay in wait for a secondary exposure to an antigen.  Plasma cells, 
                                                 
8 Janeway, 310. 
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which additionally express CD135 and CD38, return to the bone marrow and secrete 
large quantities of antibody molecules to fight an infection.9
Throughout the maturation process, diversity is generated between B cells as the 
B cell receptor (or 
antibody) molecule 
undergoes a series of 
changes.  These changes 
happen on the level of 
the genes encoding the 
receptor, and take place 
sequentially as the cell 
matures.  Both the heavy chain and the light chain are encoded by a collection of gene 
segments called V, J, and C genes; additionally, the heavy chain genes also include D 
genes.  These gene segments are rearranged through recombination to produce a 
complete antibody molecule.  First, during the transition from stem cell to large pre-B 
cell, the heavy chain of the B cell receptor is arranged by the joining of a D and a J 
segment followed by V-DJ joining.  The VDJ segment is then joined to a C region.  Cµ is 
the first C region to connect, but isotype switching may occur to connect the VDJ 
segment to different C regions later.  Following the construction of the heavy chain, the 
light chain is constructed in a similar manner, beginning with V-J joining and ending 
with the VJ segment connecting to a Cκ or Cλ gene.10
Normal human B cell maturation. 
                                                 
9 Janeway y, 310. 
10 Janeway, 310. 
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Because many possibilities exist for each gene segment that is chosen, there are a 
multitude of possible antibody molecules that can be created through this 
rearrangement alone.  The areas of greatest diversity in antibody molecules are called 
the hypervariable regions, and it is these regions that determine which antigen the 
antibody molecule will bind to.  In addition to simple rearrangement of gene segments, 
hypervariable regions are given even greater diversity through the action of proteins 
called RAG-1 and RAG-2, which randomly cut at the recombination signal sequences 
(RSS) to create slightly differential splicing even between antibody molecules with the 
same gene segments.  The variability in gene segments creates many different possible 
antibody molecules, each capable of binding a different epitope on an antigen.11
In addition to the diversity generated by the initial rearrangement of genes for B 
cell receptors, a phenomenon called isotype switching (or class switching) amplifies the 
number of possible antibodies that can be produced.  To complete the initial 
arrangement of the heavy chain, the VDJ segment is initially joined to a C segment 
called Cµ, which encodes antibody molecules of the class IgM.  In some cells, Cδ is joined 
instead, and the antibody molecules are of the class IgD.  Later in the development of 
the cell, the B cell receptor may change its C region to Cγ, Cα, or Cε, encoding IgG, IgA, or 
IgE, respectively.  The isotype switching process generates antibodies to the same 
epitopes that may be of a different class from other antibodies that are produced.  
Because each class of antibodies has a different function, this enables the immune 
system to fight an infection in many ways. 
As if VDJ rearrangement and isotype switching were not enough to generate a 
diverse B cell repertoire, an additional mechanism exists for creating an even greater 
                                                 
11 Janeway, 269. 
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variety of B cells.  Upon encountering an antigen and becoming activated, a B cell may 
rearrange amino acids in the hypervariable regions of its antibody molecules.  This 
process, termed somatic hypermutation, involves an enzyme called activation-induced 
cytidine deaminase, or AID.  During somatic hypermutation, point mutations are 
introduced into the V regions of the heavy and light chains, in the region where the 
antibody molecule contacts the antigen.  AID recognizes a specific motif in the 
nucleotide sequence of the DNA and selectively deaminates cytosine residues, which are 
then excised by another enzyme and randomly replaced.  Somatic hypermutation can 
have one of three effects: there can be no change in the antibody’s affinity for the 
epitope; the antibody can lose affinity for the epitope; or the antibody could increase in 
affinity for the epitope.  The final option, termed affinity maturation, is the reason that 
somatic hypermutation occurs.  After the B cell is activated, affinity maturation helps to 
create antibodies that have even higher affinity for the antigen, resulting in a more 
effective secondary response to a pathogen.12
The processes of VDJ rearrangement, isotype switching, and somatic 
hypermutation all introduce a large amount of diversity to the B cell repertoire, both 
before and after B cell activation.  Some of the diversity that is generated is not 
desirable, however, as B cells may become reactive toward self-generated substances.  
This reactivity toward self, termed autoimmunity, can cause serious disease.  In order to 
curb autoimmunity, the development of lymphocytes encourages self-tolerance through 
negative selection mechanisms.  Throughout various stages of B cell (and T cell) 
development, those cells that react too strongly with self-antigens are deleted, via 
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apoptosis, from the lymphocyte repertoire.  Autoimmunity and self-tolerance 
mechanisms will be covered more in depth in Section VIII of the thesis. 
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Section VI: T Cell Dependent and T Cell Independent Activation 
 
In order for B cells to carry out their effector functions, they must first be 
activated by encountering the pathogen for which they are specific.  Antigen recognition 
is not the only necessary thing for activation, however; in most cases, B cells must also 
receive a signal from T cells, and in other cases, they must receive a special kind of 
signal from the pathogen.  These two types of responses are termed thymus-dependent 
(TD) and thymus-independent (TI) humoral responses.  While the TD response is more 
typical, TI responses are also important to the ability of the organism to fight 
pathogens.13
In the thymus-dependent response, an antibody response by B cells requires help 
from T cells which recognize the same antigen.  This critical interaction of a B cell and T 
cell specific for the same antigen is termed linked recognition.  The B cell and T cell need 
not recognize the same epitope on the antigen; they must only recognize epitopes on the 
same antigen molecule.  In order for a B cell to be fully activated, it must receive help 
from an activated helper T (TH) cell.  A TH2 cell, which activates B cells, can be activated 
by any antigen-presenting cell displaying its cognate antigen on an MHC class II 
molecule, including B cells that have internalized a pathogen and presented it.  Upon 
recognizing an antigen, a B cell will travel to the border between the T cell zone and B 
cell zone of the lymph node, where it will attempt to encounter a TH2 cell with the same 
specificity.  If the endeavor is successful, a TH2 cell will activate a B cell via the 
interaction between the receptor CD40 on the B cell and the ligand CD40L (also called 
CD154) on the T cell.  The activation also involves the secretion of cytokines such as IL-
4.  The T cell-B cell pair then begins to proliferate and differentiate, forming a structure 
                                                 
13 Janeway, 369. 
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called the germinal center.  From the germinal center, cells are released that become 
plasma cells, traveling through the periphery to the bone marrow and spleen to secrete 
antibody molecules.  In the model of a TD humoral response, helper T cells are 
necessary to  create an effective antibody response to a pathogen.14
Although the thymus-dependent response is the typical mechanism of humoral 
response, in some cases B cells do not require the help of T cells in order to become 
activated.  The thymus-
independent (TI) response 
often occurs in the case of 
components of bacteria and 
other microbes, such as 
bacterial polysaccharides 
and polymeric proteins.  
These antigens are termed 
TI antigens because of their 
ability to elicit a TI humoral 
response.  In addition to the 
recognition of TI antigens, a B cell will receive a second signal either from the 
recognition of a high concentration of a common microbial component, or by excessive 
cross-linking of the BCR.  The difference in the second signal for activation is what 
distinguishes TI-I from TI-II responses.15
Typical T cell dependent and T cell independent responses.  Note the 
difference in the resulting cells and antibodies produced.  Figure 
created using VisiScience ScienceSlides program. 
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In a TI-I response, the pathogen possesses the ability to directly induce the 
activation and proliferation of B cells.  One example of a TI-I antigen is LPS, a 
component of gram-negative bacterial cell walls.  At high concentrations of this type of 
antigen, many B cells will be activated and induced to proliferate regardless of their 
antigen specificity.  This type of activation is called polyclonal activation.  At low 
concentrations of the same antigen, however, only B cells which are specific for a surface 
molecule of the pathogen will be activated. 
In contrast to a TI-I antigen, TI-II antigens contain no intrinsic ability to induce 
proliferation in B cells.  TI-II antigens are typically bacterial polysaccharides which are 
extremely repetitive on the surface of the pathogen.  These antigens can activate only 
mature B cells, and are able to activate the cells through a large amount of BCR cross-
linking.  For this type of antigen, a critical density is necessary: at concentrations that 
are too low, the antigen is unable to create enough BCR cross-linking to activate the B 
cell, and at concentrations that are too high, the cell becomes so highly activated that it 
commits suicide via apoptosis.  The most instrumental B cell types in TI-II responses 
are the less typical types, B-1 cells and marginal zone (MZ) B cells.16
It should be noted that while TI antigens are efficient at activating B cells and 
may do so more quickly than TD antigens because of the lack of requirement for T cells, 
TI responses are largely inefficient at inducing B cell memory.  This means that TI 
responses are instrumental in primary infections, but while the same TI response may 
be induced upon a secondary introduction of a pathogen, the secondary response to the 
pathogen will be no quicker or stronger than the primary response.17
                                                 
16 Janeway, 385-386. 
17 Janeway, 369. 
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In examining the reactions of B cells to certain types of activation, it is critical to 
remember the difference between thymus-dependent and thymus-independent 
responses.  These responses take place through different pathways and are useful for 
different types of infection.  Later in this thesis, we will return to the theme of TD vs. TI 
response as we encounter various types of activation for B cells. 
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Section VII: Summary of B Cell Functions 
 
Most B cells begin their development as hematopoietic stem cells in the bone 
marrow of an organism and differentiate through many stages.  Each stage of 
development is marked by a rearrangement of part of the genes that encode the B cell 
receptor, and can be followed by monitoring the markers expressed by the cell.  After 
many transitional stages, a hematopoietic stem cell differentiates to become an 
immature B cell and leaves the bone marrow.  In the periphery, the cell encounters 
antigen and becomes activated.  The recognition of an antigen by a B cell depends on the 
antigen being at least partially intact, so that the epitope that is recognized by the cell is 
preserved.  Upon activation by antigen recognition and by a second signal, a B cell will 
stop migrating, grow, and proliferate. 
The mature B cells that arise from the activation of one cell have a major career 
decision to make: they must become plasma cells, which secrete antibody, or memory 
cells, which undergo somatic hypermutation and respond strongly upon a second 
introduction of a pathogen into the organism.  Both types of cell are extremely helpful to 
the body in combating certain types of pathogen. 
In general, B cells are most useful in controlling invasions by extracellular 
pathogens.  This is only logical, as antibodies can not reach pathogens inside cells.  
Because T cells can not recognize whole, unpresented antigen molecules, B cells are 
instrumental in fighting pathogens that spend at least a significant portion of their life 
cycle outside of the cell.  Antibodies secreted by plasma cells have three primary 
functions in creating the humoral immune response.  First, antibodies can neutralize 
pathogens such as viruses and intracellular bacteria by binding to the cell surface and 
making the pathogen unable to enter the body’s cells.  Neutralization is also helpful in 
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preventing bacterial toxins from entering cells.  Second, antibody molecules can mark a 
pathogen for destruction by phagocytosis, a phenomenon called opsonization.  Finally, 
antibodies can activate the complement protein system, causing the proteins to bind to 
the pathogen and opsonize the pathogen.18
Because the antibody response takes time to form, it is typically more helpful 
during a secondary response than a primary response.  While other mechanisms of 
immunity may be more effective in clearing the pathogen during a primary response, 
antibodies from memory B cells are extremely effective in stopping an infection upon a 
second introduction of a pathogen. 
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Section VIII: Autoimmunity & Cancer: When the Immune System Goes Wrong 
 
While the immune system is typically highly regulated and specifically targeted, 
there are cases in which some form of regulation can be turned off, or changed, so that 
the immune system is no longer as finely tuned as it normally is.  When this occurs, part 
or all of the immune system can become extremely dangerous to the individual.  Two 
cases in which dysregulation of the immune response is harmful include autoimmunity 
and cancer. 
Because many infections can become serious if not effectively cleared, the 
immune system must by necessity contain many potent methods for combating 
pathogens.  The immune response is not necessarily limited to fighting pathogens, 
however; if not properly regulated, it can just as easily be directed against the body 
itself.  Luckily, in most individuals, the cells of the immune system are highly regulated 
and contain mechanisms for ensuring self-tolerance.  Autoimmunity is not an extremely 
rare phenomenon, however; estimates indicate that approximately 5% of Americans 
suffer from some sort of autoimmune disease.19
An autoimmune response can be characterized as either organ-specific, 
concentrated primarily within one organ, or systemic, spread throughout the body.  
Some examples of organ-specific autoimmune disease include Graves’ disease, type I 
diabetes mellitus, multiple sclerosis, and myasthenia gravis.  Some examples of systemic 
autoimmune disease are systemic lupus erythematosis (SLE), Sjögren’s syndrome, and 
rheumatoid arthritis.  In addition to the distinction between organ-specific and systemic 
disease, autoimmune disorders can be primarily antibody-mediated, T-cell-mediated, or 
                                                 
19 Sompayrac, 100. 
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both, although nearly all autoimmune disorders require both B cells and T cells to fully 
develop the disease.20
During the development of lymphocytes, cells which react strongly to self-
antigens undergo a negative selection, resulting in the apoptosis of these cells.  This 
negative selection ensures that surviving lymphocytes will be tolerant of self antigens.  
While the distinction between self and non-self is still being studied and the specifics are 
not yet clear, results thus far indicate that the distinction is made both by the stage of 
development at which the cell encounters an antigen and by the concentration levels of 
the antigen.21  In most individuals, this self-tolerance mechanism works very well, with 
only a few autoreactive cells escaping negative selection.  In some individuals, however, 
genetic defects cause problems with the mechanisms that control lymphocytes.  In these 
individuals, many autoreactive cells escape self-tolerance mechanisms, and 
autoimmunity almost certainly develops.  Although autoimmunity frequently arises in 
individuals with a genetic predisposition, it is possible for genotypically normal 
individuals to develop an autoimmune disease because even functional self-tolerance 
mechanisms are not 100% effective in eliminating autoreactive cells.22
In individuals who are not genetically predisposed to autoimmune disorders, 
autoimmunity typically results from a change in lymphocytes with a low affinity for self 
antigen.  Low-affinity lymphocytes will not be activated by self antigen, however, they 
can be activated by stimulation with a high amount of co-stimulatory molecules such as 
cytokines or by stimuli similar to the self-antigen, such as DNA from pathogenic 
bacteria.  Once these lymphocytes are activated, they can become more highly reactive 
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22 Sompayrac, 100. 
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against self antigens, either through a high level of activation and proliferation or 
through somatic hypermutation.  In accordance with the idea that many autoimmune 
reactions are initially directed at non-self pathogens, a large percentage of autoreactive 
antibodies are directed at DNA.  In addition, toll-like receptors (TLRs), which are 
typically involved in innate and innate-like immune recognition of common microbial 
components, have been implicated in the mediation of autoimmune disease.23
Once an autoimmune reaction begins, it can easily become a chronic disorder.  
Because self antigens are frequently ubiquitous and difficult or impossible to clear from 
the system, an autoimmune response can be hard to stop once it has begun.  In addition, 
an autoimmune response can be directed toward more than one epitope on a self 
antigen or other proteins in a tissue, a phenomenon called epitope spreading.  
Autoimmunity can also be fueled by the consequences of an immune reaction in a tissue, 
including inflammatory cytokines and the new availability of self antigens as a result of 
cell death.  Because of these possibilities, most autoimmune disorders are chronic, and 
many worsen as the disorder persists.24
In addition to autoimmunity, cancer can also result if the cells of the immune 
system are not properly regulated.  In order for a normal cell to become cancerous, 
many changes must occur.  The cell must lose the property of regulation of proliferation, 
usually because of mutations in cell-regulatory genes.  In addition, tumor cells must be 
able to generate their own blood vessels, a property known as angiogenesis.  Cancerous 
cells also lose the dependency upon contact for growth, causing them to be able to grow 
                                                 
23 Janeway, 569-570. 
24 Janeway, 564-570. 
  33 
on top of other cells and also be able to metastasize, or detach and move to other 
locations.25
If blood cells such as lymphocytes are affected by the changes that cause cancer, 
blood cancers such as lymphomas and leukemias result.  In cases of leukemia, immature 
lymphocytes fill up the bone marrow, where they prevent other cells from maturing; in 
lymphoma, clusters of cells that resemble tumors form in the lymph nodes.  Leukemia 
and lymphoma can both result from mutations in either B cells or T cells, and are 
typically serious diseases.26
In B cells, malignancies can occur at any stage of development.  Precursor B cell 
neoplasms such as lymphoblastic lymphoma (LBL) and B-cell acute lymphoblastic 
leukemia (B-ALL) occur predominantly in children and young adults and are signified 
by the lack of Ig expression in the cancerous cells.  Peripheral mature B cell neoplasms 
such as B cell lymphomas and B cell chronic lymphocytic leukemia (B-CLL) occur 
primarily in older individuals.  B-CLL is signified by a large amount of small, round B 
cells with a low surface expression of Ig but a high expression of CD19 and CD5.  These 
cells express surface markers that come from different stages of development, making it 
difficult to determine which cell stage is the precursor to the cancerous cells.27
B cell lymphomas are typically characterized as either representing Hodgkin’s 
disease or being part of a class of diseases termed non-Hodgkin’s lymphomas (NHL).  
Until recently, Hodgkin’s disease was thought to derive from T cells or some other 
precursor, but after further investigation, it is currently accepted that the precursor cell 
of Hodgkin’s disease is the Reed-Sternberg (RS) cell, which derives from post-germinal 
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26 Janeway, 305. 
27 Jelinek & Darce, “Human B Lymphocyte Malignancies: Exploitation of BLyS and APRIL and Their Receptors,”  
268-269. 
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center B cells that have rearranged their Ig molecules but do not express them on the 
cell surface.  Non-Hodgkin’s lymphoma encompasses many different types of 
lymphoma, including diffuse large B cell lymphoma (DLBCL, the most common type of 
non-Hodgkin’s lymphoma), follicular lymphomas, Burkitt’s lymphoma, and marginal 
zone lymphoma.  Each type of lymphoma is characterized by a different type of 
precursor cell and manifests itself differently in affected individuals.28
In addition to leukemias and lymphomas, other types of plasma cell 
transformations also occur.  Multiple myeloma (MM) is a monoclonal expansion of 
plasma cells, resulting in a high number of malignant plasma cells found in the bone 
marrow and sometimes in the periphery, as well as a large volume of secreted Ig, 
typically found in the serum and urine of affected individuals.  The regulation of cell 
growth and expansion seems to be extremely complex in MM.  Other plasma cell 
transformations include lymphoblastic lymphoma, which affects a variety of B lineage 
cells at different stages, and B cell related amyloidosis, which results in amyloid deposits 
of light chains from Ig molecules.29
Many different methods of targeting and controlling tumors are currently being 
investigated by researchers or in use as therapy.  Most of these involve targeting what 
are termed tumor rejection antigens, specific markers that are only present on tumor 
cells.  Tumor rejection antigens can be targeted by antibodies specific for the antigen or 
by a cytotoxic T cell response, or both.  Ideally, targeting these markers should ensure 
that only tumor cells are killed and that the body’s normal cells are not harmed in the 
immune response.  In addition to targeting these cells for destruction, methods such as 
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viral gene therapy can use the same tumor markers to direct genes that inhibit growth or 
angiogenesis toward only the tumor cells.  This method typically involves replacing 
mutated genes or integrating new genes to introduce a new method of controlling the 
cells.30
Both autoimmunity and cancer are serious problems which directly or indirectly 
affect a large percentage of the population.  Because of this, much time and funding has 
gone toward finding effective therapies for both disorders.  Although a singular cure for 
either cancer or autoimmune disorders is likely impossible, methods of treating specific 
types of disease will improve as time goes on and society’s knowledge of science 
increases.  Through studying different types of cancer or autoimmunity, and through 
studying how cells are regulated, the scientific community comes closer to 
understanding how these problems can best be treated. 
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Section IX: Lipid Rafts 
 
In contrast to what is told to every Introductory Biology student, the lipids in a 
cell membrane are not as uniformly distributed as the “fluid mosaic” model indicates.  
In fact, different types of lipids form membrane microdomains, portions of the cell 
membrane composed of a large percentage of a particular type of lipids and their 
associated proteins.  The most well-characterized membrane microdomain is the lipid 
raft, which is also called a glycolipid-enriched microdomain (GEM) or detergent-
insoluble glycolipid-rich domain (DIG).  Lipid rafts are cholesterol- and sphingolipid-
rich membrane microdomains which also contain many proteins that are either 
constitutively associated with the lipid raft or recruited to the raft under certain 
conditions.  Many of the raft-associated proteins are kinases, which are associated with 
the lipid rafts in order to aid in activating cell signaling cascades. (1) 
Lipid rafts are typically present in small, sub-microscopic domains in resting 
cells, spread out evenly 
throughout the cell surface.  
Upon activation of the cell, 
however, these small lipid rafts 
can aggregate, forming one or 
more large clusters on the surface 
of the cell.  When lipid rafts 
cluster, they bring together many proteins and receptors which are associated with them 
and exclude others.  While unclustered rafts are not easy to visualize, when rafts cluster 
they appear to represent as much as 40% of the cell membrane.  As of yet, it remains 
unclear whether lipid raft clustering is the first event following cell activation, or if raft 
Lipid Rafts on the surface of a resting cell are small and 
distributed throughout the surface.  Upon stimulation of the cell, 
the rafts cluster into one large raft domain.  Figure created using 
VisiScience ScienceSlides graphics. 
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clustering is a result of other receptors or proteins being induced to aggregate.  
Regardless of which event occurs first, evidence indicates that some receptors are nearly 
always associated with lipid rafts, while others are only associated under certain 
conditions. (2) 
When lipid rafts cluster, they are extremely useful as signaling platforms for the 
cell, and are also thought to be a critical part of the formation of the immunological 
synapse.  Because of raft-associated kinases and other proteins that are extremely useful 
in signaling cascades, when receptors are recruited to lipid rafts they are usually 
activated and signaling begins.  Cross-linking of the BCR and the subsequent association 
of the BCR with lipid rafts has been extensively studied, and it appears that BCR 
signaling only begins in significant amounts following the association of the BCR with 
lipid rafts.  It has also been suggested that lipid rafts may play an important role in the 
BCR-mediated endocytosis of pathogens.  Along the same line, lipid rafts have also been 
implicated in some viral infections of cells, as they tend to cluster molecules necessary 
for access into the cells.  Viruses that utilize lipid rafts to enter cells include HIV, Ebola, 
and the Epstein-Barr and Marburg viruses. (2, 3) 
While the association of a receptor with a lipid raft is typically thought to increase 
the amount or effectiveness of cell signaling, many researchers have suggested that raft 
association may also decrease the effectiveness of certain signaling pathways.  A model 
proposed by Kwang-Il Lim and John Yin at the University of Wisconsin, Madison, uses 
biophysical concepts to create an electrical circuit analogy and statistical equation for 
ligand binding to clustered receptors.  The model proposes that raft-mediated receptor 
clustering can limit ligand binding because the ligand must first reach the cell surface, 
then find the clustered lipid raft area, then find its appropriate receptor.  This model can 
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be used to explain instances in which lipid raft association does not aid the signaling of a 
particular molecule or receptor. (35) 
Because of the many important functions that lipid rafts seem to have, many 
methods have developed for studying lipid raft formation and raft association of 
proteins.  In order to understand what functions depend on lipid rafts, researchers 
frequently use a technique called cholesterol depletion, which employs a substance 
(often cyclodextrin or glucocorticoids) that removes cholesterol from the cell membrane.  
Various processes in the cell can then be studied to determine if they take place as 
normal when lipid rafts cannot form.  Through this method, it has been shown that the 
localization of many receptors depends on lipid rafts.  In addition to cholesterol 
depletion, the association of molecules with lipid rafts has also been studied through gel 
electrophoresis.  As the name implies, as detergent-resistant microdomains, lipid rafts 
can easily be isolated from other cell components by lysing the cell with detergent and 
removing all soluble molecules.  The cell components remaining after treatment with 
detergent are the lipid rafts and their associated receptors, which can then be analyzed 
with SDS-PAGE or 2D gel electrophoresis techniques. (2, 4) 
While the technologies of cholesterol depletion and detergent treatment have 
been extremely useful in studying lipid rafts, they do have their limitations.  Detergent 
treatment of cells lyses the cells, making studying their signaling processes in addition 
to the presence of the signaling molecules impossible; additionally, gel electrophoresis 
can be ineffective in detecting small amounts of a protein, meaning that it is difficult to 
study a receptor that is present in small amounts on the cell surface.  Cholesterol 
depletion is highly controversial as a technique for studying living cells, as it can heavily 
disrupt many processes in the cell, making it difficult for the cell to recover.  Because of 
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these limitations, less invasive methods of studying lipid rafts have developed.  
Visualization using lipid raft markers provides a non-invasive alternative to studying 
cell membrane dynamics and signaling processes.  The most common marker for lipid 
rafts is the ganglioside GM1, which can be visualized by staining with the B subunit of 
the cholera toxin molecule, conjugated to a fluorescent molecule such has GFP or FITC.  
GM1 has been shown, through many different experiments, to associate with lipid rafts 
in mature B cells, an extremely important fact to remember when reading the end of this 
thesis.  (4, 5) 
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Section X: Cell Polarization and Signaling 
 
When lymphocytes are activated, they often assume a polarized morphology.  
This occurs as part of cell migration and very often as a part of intercellular signaling.  
Polarized lymphocytes have two very different ends: a leading edge, at the front of the 
cell, and a trailing edge, or uropod, at the rear of the cell.  Each end may have associated 
lipid rafts, a specific protein composition, and many discrete functions.  The leading 
edge of a polarized lymphocyte is thought to be composed of receptors that recognize 
chemokines, chemical signals which tell the cell to move in a certain direction.  It also 
contains many substrate-adhesion molecules, which help the cell stop migrating and 
enter an infected area or special compartment of the body.  The trailing edge, or uropod, 
contains molecules associated with endocytic trafficking in the cell, as well as those 
necessary for intercellular adhesion.  The molecules associated with the separate ends of 
the cell are thought to be related to the functions of each end, and in many cases this 
line of thinking has been backed up by experimental results. (6) 
When a lymphocyte becomes polarized, the cell membrane typically reorganizes, 
with some receptors forming a “cap” at one end of the cell.  This reorganization is 
generally thought to be mediated by changes in the cytoskeleton and by lipid raft 
clustering.  In accordance with this idea, some of the markers of the trailing edge of the 
cell have been shown to be physically associated with cytoskeletal elements such as actin 
and tubulin.  (6, 7)  In some studies, the formation of a receptor cap in the uropod has 
been found to be blocked by cytochalasins, which block actin polymerization.  This data 
indicates that actin has a large role in cell polarization and receptor localization in 
polarized cells.  Interestingly enough, colchicines, which block microtubule 
polymerization, have been found to not interfere with the formation of a receptor cap at 
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the uropod, indicating that while some receptors may be associated with tubulin, 
microtubules likely do not play a role in uropod formation.  (7)  Other studies have 
shown that when cells become polarized, molecules such as syndecan-1 and syndecan-4 
may be involved in the sequestering of receptors in lipid rafts, particularly in the uropod 
of the cell.  (9) 
Many studies have examined the role of cell polarization in lymphocytes.  
Typically, this involves either determining the effect of cytoskeletal rearrangement on 
cell surface molecules or examining 
receptor localization in polarized cells by 
visualization of the receptor of interest.  
While the first technique is relatively 
simple and usually involves disruption 
of the cytoskeleton, the second 
technique can be slightly more 
complicated.  First, a reliable marker of 
cell polarization must be found.  This involves testing various cell surface molecules to 
determine which molecules segregate reliably to either the leading edge or the uropod of 
the cell.  Following the discovery of a good marker, a co-staining procedure must be 
performed to determine whether the molecule of interest co-localizes with the marker.  
Many markers of cell polarization have been found in T cells, as many polarization 
experiments have been conducted in T cells.  The ganglioside GM1, a marker of lipid 
rafts, has been found to segregate to the leading edge of polarized lymphocytes, as has 
CD11a (also known as LFA-1) and F-actin.  Characterized uropod markers include CD44, 
CD43, ICAM-1, and PSGL-1 (CD162), all cellular adhesion molecules. (8, 9)  Antibodies 
A polarized B cell.  Leading edge and trailing edge 
markers are shown. 
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and fluorescently-labeled antibodies to all of these molecules have been created and are 
widely commercially available.  As with lipid rafts, the study of receptor localization 
through visualization helps the researcher examine cell processes in intact, healthy cells, 
making it much more likely that the results being found are representative of what 
occurs in vivo. 
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Section XI: The BLyS/APRIL System – Novel TNF Family Members 
 
One major family of cytokines that has been extensively characterized is the 
tumor necrosis factor, or TNF, family.  The TNF family is a group of proteins with 
homology to the original tumor necrosis factor protein.  All of these proteins form 
trimers, and many TNF family members are membrane-bound.  The TNF family of 
proteins and TNF receptors has many functions in innate and adaptive immunity, 
possessing stimulatory and anti-stimulatory functions.  Examples of widely known TNF 
family members include CD40 ligand (CD40L), which is expressed by CD4+ T cells, and 
Fas ligand (FasL), which is expressed by CD8+ T cells.  While CD40L commonly 
stimulates B cells to proliferate, FasL directs many cell types to undergo apoptosis.  
Defects in the FasL apoptotic pathway result in lymphoproliferative diseases and 
autoimmunity, a rare instance when autoimmunity is caused by a defect in a single gene.  
While many TNF receptors, like Fas, have “death domains” in their cytoplasmic tails, 
some, such as CD40, lack this domain and act through TNF-receptor associated factors, 
or TRAFs. (1) 
Two novel ligands in B cells have recently been identified as a part of the TNF 
family.  B cell lymphocyte stimulator, BLyS (also known as BAFF, zTNF4, THANK, 
TALL-1, and TNFSF-13b), and a proliferation inducing ligand, APRIL (also known as 
TALL-2, TRDL-1, and TNFSF-13a), are some of the most recent additions to the tumor 
necrosis factor family.  These ligands, as well as their three known receptors and one 
additional binding partner, have been found to have a role in cell proliferation and 
apoptosis.  Because of their function in B lymphocytes, this ligand/receptor family has 
been thought of as a potential target for treatments against autoimmunity and B cell 
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malignancies, and many experiments have sought to determine the role of BLyS and 
APRIL in various types of autoimmune disease and cancer. (10) 
B lymphocyte stimulator, or BLyS, is a TNF family member that is commonly 
thought of as an enhancer of B cell survival.  The BLyS locus is on human chromosome 
13q34.  BLyS is expressed on myeloid 
lineage cells and is upregulated by 
inflammatory cytokines such as IFN-
γ and IL-10.  It has been shown to 
attenuate apoptosis, heighten the 
humoral immune response, and co-
stimulate a CD40L response, 
perhaps by increasing the ability of 
the B cell receptor to phosphorylate 
the coreceptor CD19.  Because it is a 
critical survival signal, newly formed 
and mature B cells compete for BLyS 
to extend cell survival.  Mice that are 
deficient in BLyS have a reduction in peripheral B cells after the T1, or first transitional, 
stage of development, with the exception of B1 cells, which are thought to go through a 
different developmental pathway.  These mice also have a reduced T cell independent 
and T cell dependent humoral response.  (11)  When BLyS acts through its primary 
receptor, BAFF-R, it acts as a survival factor, allowing B cells to avoid apoptosis.  
Through both its soluble form and its membrane-bound form, it also acts as a B cell 
The BLyS and APRIL system of ligands and receptors.  
BLyS binds to BAFF-R, BCMA, and TACI, while APRIL 
binds to BCMA, TACI, and proteoglycans. 
Figure courtesy of Jaime Darce. 
maturation signal, mediating class switching in maturing B cells. (10, 12, 14) 
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Normal B cells maintain homeostasis through a balance of production, survival, 
proliferation, and apoptosis.  Abnormal production of BLyS can disrupt this balance and 
disturb
e of its 
recepto
r, BAFF-R (or BR3), as well as B cell maturation antigen 
(BCMA), and transmembrane activator and CAML interactor (TACI).  APRIL, like BLyS, 
 tolerance, resulting in cancer and autoimmunity.  This is evidenced by the fact 
that mice that are transgenic for BLyS overexpression develop autoimmune symptoms 
and B cell lymphomas, and also by the fact that serum levels of BLyS are elevated in 
human patients with autoimmune diseases and B-lymphoid malignancies.  (12) 
A proliferation-inducing ligand, or APRIL, is a cytokine which was first 
characterized by enhancing proliferation in B cells when it interacts with som
rs, but it can also repress proliferation through its interaction with the receptor 
TACI.  In addition, APRIL can promote T cell independent type 2 (TI-II) responses and 
has been shown to promote IgM secretion in vitro.  The gene for APRIL is found on 
human chromosome 17p13.1, and it shares significant sequence homology with BLyS, 
making the two molecules much more similar to each other than to any other TNF 
family members.  APRIL is mainly secreted as a soluble molecule and is expressed by 
monocytes, dendritic cells, and T cells.  In addition to its functions in B cells, it is 
thought to be important for T cell activation, as anti-APRIL antibodies interfere with T 
cell stimulation in vitro.   While APRIL is thought to enhance proliferation, mice with an 
APRIL deficiency exhibit normal immune development, indicating that some of the 
function of APRIL may be redundant.  APRIL expression is higher in tumor cells than in 
normal cells, however, suggesting that APRIL may have some effect on tumor cell 
proliferation. (12, 13, 14) 
To date, there are four characterized binding partners for BLyS and APRIL.  BLyS 
binds to its own recepto
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binds t
milar to the phenotype of BAFF-
deficie
or necrosis factor, 
o BCMA and TACI, but also binds to heparin sulfate proteoglycans (HSPG) on the 
surface of cells.  Interestingly, the surface APRIL uses to bind to BCMA and TACI is 
different than the surface it uses to bind to HSPG, suggesting that it may be able to bind 
to both HSPG and another receptor at once.  (10, 15) 
Much information about the receptors for BLyS and APRIL can be gleaned from 
animals whose cells lack these receptors.  BAFF-R knockout mice display a severe 
decrease in mature B cells beyond the T1 stage, si
nt mice.  This suggests that BAFF-R is responsible for BLyS-mediated B cell 
survival.  Interestingly, it has also been discovered that the immunodeficient model 
A/WySnJ mouse strain has a natural mutation in the third exon of the BAFF-R gene.  In 
contrast to BAFF-R knockouts, which display a severe phenotype, BCMA knockout mice 
have no drastic B cell deficiency and only appear to have a slight reduction of plasma 
cells, indicating that the majority of important BLyS and APRIL signaling takes place 
through their other receptors and BCMA may act as a backup system for these receptors.  
Mice deficient in TACI display an increase in peripheral B cells, yet a decrease in T cell 
independent (TI) responses, particularly TI-II, and a defect in IgA production.  This 
surprising phenotype suggests that TACI may be a negative regulator of B cell survival, 
but may also positively regulate TI humoral responses.  In addition, these mice also 
display autoimmune disorders similar to systemic lupus (SLE) as well as B cell 
lymphomas, most likely due to the increase in peripheral B cells.  Much more 
information on TACI will be discussed in the next section. (11, 12) 
Because of their regulatory roles on lymphocyte survival and proliferation, the 
ligands and receptors of the BLyS/APRIL system have been linked to many different 
autoimmune diseases and cancers.  In the absence of tum




pression of BLyS leads to a high incidence of B cell lymphoma, and BLyS has been 
found to bind to malignant B cells from patients with B cell chronic lymphocytic 
leukemia (B-CLL), non-Hodgkins lymphoma (NHL), and multiple myeloma (MM).  
APRIL has also been shown to bind to B-CLL cells.  Malignant lymphocytes have higher 
reactivity with BLyS and APRIL than normal human plasma cells, suggesting that BLyS 
and APRIL binding might provide an alternative survival pathway for tumor cells.  In 
accordance with this idea, MM cells have been shown to survive for longer with access to 
BLyS than without it, and the bone marrow of patients with MM expresses much more 
BLyS mRNA than that of normal patients.  MM cells and B-CLL cells also express a high 
level of TACI and BAFF-R, indicating that their ligands may be responsible for at least 
some of their survival. (10, 12, 17)  In addition to their functions in cancer, BLyS and 
APRIL have also been connected to autoimmune disorders.  They appear to have both 
pro- and anti-inflammatory functions in rheumatoid arthritis (RA), and levels of BLyS 
are elevated in the serum of patients with SLE and Sjögren’s Syndrome. (10, 16, 18) 
Because BLyS, APRIL, and their receptors are intrinsically linked with 
autoimmunity and B cell malignancies, this system makes a logical target for treatment 
for these diseases.  In order to discover new ways to treat RA, SLE, MM, B-CLL,
any researchers are striving to better understand the ligands and their receptors 
in order to design strategies to prevent or encourage BLyS and APRIL binding to their 
receptors.  Treatments based on this ligand-receptor system could provide new hope for 
patients who have not yet found an effective treatment for their cancer or autoimmune 
disorder. 
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Section XII: TACI 
On
 
e of the important receptors in the BLyS/APRIL system is transmembrane 
activator and CAML interactor, or TACI, which binds to both BLyS and APRIL.  TACI 
was discovered by Götz-Ulrich von Bülow and Richard J. Bram, who were then at the 
University of Tennessee in Memphis.  Von Bülow and Bram cloned and characterized 
the gene for TACI, which is located on human chromosome 17p11.2, and created a strain 
of TACI knockout mice.  Since the first discovery of TACI, von Bülow and Bram, now at 
Mayo Clinic, as well as other researchers, have done much work to further elucidate the 
structure and function of the TACI protein in both normal and disease systems.  (14, 19) 
TACI is a type III transmembrane protein with an extracellular amino terminus 
and two repeated cysteine-rich motifs, which is characteristic of the TNF receptor 
superfamily.  Unlike many members of the TNFR family, however, TACI 
lacks a death domain in its cytoplasmic tail and must act via other 
signaling elements in the cytoplasm.  TACI is expressed in subsets of B 
cells, as well as activated CD4+ T cells, and its mRNA can be found in 
spleen, small intestine, thymus, and peripheral lymphocytes.  TACI was 
first characterized by its interaction with the protein CAML, or calcium-
modulator and cyclophilin ligand, and its subsequent activation of the 
protein NF-AT, or nuclear factor of activated T cells transcription factor.  
NF-AT activation is extremely important to lymphocyte action, and the 
CAML protein is a co-inducer of NF-AT activation, a process which is 
dependent on calcineurin.  The cross-linking of TACI appears to have an 
effect on AP-1 and NF-kB activation as well as NF-AT activation. (19) TACI.  
Courtesy of 
Jaime Darce. 
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ho now ans 
typically m diate cell adhesion, motility, proliferation, and differentiation, the binding 
ansgenic mice.  TACI knockout mice have enlarged spleens with normal 
architecture, indicative of the increased number of mature circulating and splenic B 
cells, almost double the number than that of wild type mice.  They also have a marked 
decrease in IgM and IgA, indicating defects in B cell class switching.  These knockout 
mice have a normal T cell dependent response, but impaired TI responses, particularly 
to TI-II antigens.  This phenotype resembles that of B cell lymphomas, and also 
resembles autoimmune disorders like SLE.  In contrast to the autoimmune phenotype of 
knockout mice, the administration of soluble TACI protein into mice inhibits antibody 
tion and the production of germinal centers in the spleen, and the injection of 
soluble TACI into spontaneously autoimmune mice suppresses kidney damage and 
ival in those mice.  Based on this data, it appears that TACI is a positive 
cell activation in TI-II responses, as well as a negative regulator of B cell 
(20) 
ry recent discovery, another ligand besides BLyS and APRIL has been 
I.  Syndecan-2, a transmembrane heparan sulfate proteoglycan, is a ligand 
 for TACI and does not bind to BCMA or BAFF-R.  This discovery was 
combinant TACI-Fc fusion protein as a probe in a cDNA library screen.  
s performed using 293T cells, which do not express detectable levels of 
yS or APRIL.  While it is known that BLyS binding to TACI typically 
 cell proliferation, and APRIL binding mediates TI-II responses and B1 B 
he function of syndecan-2 in binding to TACI is still unknown.  It is, 
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of syndecan-2 to TACI may mediate any of these functions.  This new development will 
certainly prove interesting in future TACI research.  (21) 









Part III: TACI Localization in B Cells 
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Section XIII: Experimental Logic 
 
As a summer student at the Mayo Clinic, I was assigned to a lab based on my 
terests, but as I had little knowledge of immunology, I was unsure of exactly what my 
interests were.  I entered the lab of Diane Je nek, unaware of what project I would work 
on and how it would turn out.  The Jelin k lab primarily focuses on molecular and 
cellular immunology and tumor biology, with a special concentration on normal and 
malignant B lymphocytes, B cell chronic lymphocytic leukemia, and multiple myeloma.  
Because I was entering into the summer with little knowledge in the field of 
immunology, the lab designed a project for me based on a side project of Jaime Darce, a 
graduate student in the lab. 
Prior to the summer, Jaime and a postdoctoral fellow in the lab, Xiaosheng Wu, 
had made some very interesting observations during the course of their research.  In 
conducting a thymidine proliferation assay to determine the effect of APRIL binding on 
stimulated B cells, they noticed an interesting discrepancy.  When primary human 
peripheral blood B cells were stimulated with cytokines (IL-2, IL-4, IL-10, IL-12) and 
CD40L, a T cell dependent stimulus, they were induced to proliferate.  The proliferative 
effect of CD40L on the B cells was stopped by the addition of APRIL at the same time as 
the CD40L, indicating that APRIL binding to TACI had a negative effect on CD40L-
mediated proliferation of B cells.  While this was what Jaime and Xiaosheng expected, 
they found that they got entirely different results when they changed the stimulus.  CpG, 
a T cell independent stimulus, also induced the B cells to proliferate when added with 
cytokines (IL-15).  When APRIL was added at the same time as the CpG, however, 
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This was a curious difference, as in each case APRIL was binding to TACI, but it was 
having
e CpG-stimulated cells.  From this observation, my Summer 
Under
for understanding this thesis, but for an in-depth background on any of these 
 different effects on the cells. 
Intrigued by the differential effect of APRIL on the stimulated B cells, Jaime and 
Xiaosheng set out to determine what might cause APRIL to signal differently through 
TACI in each case.  One of the things they examined was the localization of TACI on the 
surface of these cells.  Using fluorescent labeling and confocal microscopy, they made a 
very interesting observation: TACI was capping at one end in a small subset of the CpG-
stimulated cells, creating a polarized morphology in these cells.  Through the lower-
power confocal microscope in the lab, they saw that the receptor was localizing on one 
end of the cell, but only in th
graduate Research Fellowship project was born. 
My task, for my summer project, was to characterize the localization of TACI on 
the surface of normal human B cells under various stimuli.  For several different stimuli, 
I examined the localization of TACI using fluorescent labeling and confocal microscopy.  
Following the general characterization of TACI localization, my next job was to examine 
colocalization with markers of polarized cells and with lipid raft markers.  For someone 
unfamiliar with immunology and many of the necessary lab techniques, this was a tall 
order, but with hard work and a little luck, I was able to finish all of the goals of my 
project. 
In the next few sections of this thesis, techniques, biological molecules, and 
concepts will be briefly described in a glossary format.  The aim of these sections is to 
provide a general background on the techniques used in my summer research and the 
reagents and equipment used in these techniques.  This background should be sufficient 
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techniques, it would be best to search scientific papers, manufacturers’ websites, or the 
internet for more information. 
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Section XIV: Glossary of Methods and Molecules of Interest 
The following is an overv
 
iew of the techniques and molecules used in my project, 
listed in the order of their use in the project.  This glossary is intended to provide a very 
general background of the techniques.  For a more detailed background to any of the 





The layer of white/yellow plasma from which the red blood cells have settled out; 
primarily contains white blood cells.  (22)  When blood centers get donations, they must 
filter out the white blood cells and platelets before blood can be used for a transfusion.  
The buffy coat is used for research or other medical purposes. 
 
Cell Isolation – Density Centrifugation 
Isolating a particular group of cells from a larger group of 
cells or a solution (i.e. from a buffy coat).  Cell isolation can 
be done by density gradient centrifugation, which uses a 
density gradient (such as that established by the sugar 
Ficoll) to separate cells by density.  Ficoll solution can be 
added by underlaying beneath the cells (which are suspended in a solution of saline).  
The cells are then spun in a centrifuge, which forces the more dense matter to the 
bottom of the tube.  To isolate white blood cells from a buffy coat, the middle layer that 
floats between the clear and red layers is removed for further purification. 
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Washing Cells 
Cells m
cess of magnetically labeling and sorting 
ells.  Cells can be labeled with an antibody attached 
ic bead and sorted based on the marker 
 The cells are sorted by running them 
enyi Biotec, Inc.  (23) 
he type of cell and length of 
ntibiotics added.  Primary 
onger if stimulated.  In cell 
int to study the effect of the 
ay be “washed” for purification by adding saline and spinning the cells in a 
centrifuge. 
 





through a magnetic column, which sorts the cells 
based on being positive or negative for the magnetic 
bead.  Positive, double positive, and negative selection can be performed.  The 





































Cell Culture & Stimulation 
Cells can be cultured by placing them in a media and incuba
for studying the cells at a later time.  The media depends on t
the culture period, and may have additional nutrients or a
human B cells may last up to 5 days without a stimulus, and l
culture, any stimulus can be added to the cells at any time po
stimulus, either short term or long term.  In the case of lymphocytes, these stimuli are 
typically coupled with cytokines to mimic an in vivo immune response.  The cells can be 
removed from culture and isolated from the media in order to be studied further.  (24) 
 
ting them, in order to allow 
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Labeling Cells with Antibodies 
odies will label the location of a particular molecule.  If the antibodies are 
ttached to a fluorescent molecule, such as GFP or FITC, the molecule that the 
icroscope or selectable in flow 
nd adding fluorescently label
 be added to identify a particu
onfocal microscopy is a method of 
h-
g 
echnique.  Moving the focus plane during imaging allows for “optical slices” of the 
Antibodies can be made to a biological molecule through many different methods.  
These antib
a
antibodies identify will be clearly visible under a m
cytometry. 
 
The typical process of labeling cells involves fixing the
they are in and permeabilizing the membrane) a
antibodies.  In addition to antibodies, ligands can also
receptor or molecule. 
 
Confocal Laser Scanning Microscopy 






microscopy used to obtain hig
resolution and 3D images.  The 
microscope has a pinhole sitting 
conjugal to the plane of light 
(confocal), which keeps light from other planes from hitting the detector.  This method 
allows for blur-free samples of thick specimens.  The laser scanning microscope scans 
the specimen point by point and line by line, and reassembles the image on a computer 
screen.  Multiple scans of the specimen using this method aids in enhancing image 
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specimen to be taken, making it possible to create and analyze a three dimensional stack 
microscopy has greatly enhanced the technique.  Fluorescent microscopy 
xploits the excitation and emission spectra of fluorescently labeled antibodies and 
e same idea, confocal technology can be used for more advanced 
urposes, such as FRET, FRAP, or FLIP, which further exploit the excitation 
cules to make more concrete observations 
s can be found online which thoroughly summarize 
of the slices after imaging.  Confocal microscopy is an incredibly diverse and useful 
technology for biomedical research. 
 
While confocal microscopy can be used for bright field images, the ability to do 
fluorescent 
e
other molecules in order to capture the location of certain molecules in an image.  
Multiple wavelengths of light can be used to image molecules with labels of different 
colors, and most confocal microscopes have two or more wavelength channels for this 
purpose.  Following th
p
wavelengths of fluorescently labeled mole
about the molecules of interest.  W
thesis, many very interesting review
the use of each.  (25) 
 
hile these technologies are beyond the scope of this 
Reagents 
Saline 
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Ficoll 
Also called Isolymph, Ficoll is a sugar solution used to set up a density gradient in 
density gradient centrifugation.  Ficoll is useful in separating a certain cell type from a 
olution based on density of the cells. 
ith biotinylated antibodies.  The magnetic beads bind to the 
iotinylated antibodies, labeling the cells for magnetic cell sorting using AutoMACS. 
to support the growth of human cells.  Additional nutrients or 
ntibiotics may be added to the medium to ensure the proper growth of cells. (26) 
s
 
MACS Selection Cocktail 
MACS selection cocktail is a solution of biotinylated antibody (or antibodies) used to 
select for a particular molecule on the surface of a group of cells.  The antibody is 
biotinylated, making it possible to magnetically label the antibody with magnetic colloid.  
The combination of selection cocktail and magnetic colloid is used for selection in 
AutoMACS cell sorting.  In the experiment described in this thesis, the selection cocktail 
used was for CD19, a cell surface marker of B-lineage cells. 
 
Magnetic Colloid 
More simply termed magnetic beads, magnetic colloid is a solution added to cells that 













A cell surface molecule that makes up part of the B cell co-receptor.  CD19 is often used 
s a marker of B-lineage cells for flow cytometry and cell sorting.  In this experiment, 
 cell sorting. (1) 
.  It is essential for TD 
esponses.  In the experiment described in this thesis, CD40L was used with IL-2, IL-4, 
stimulate the B cells. (1) 
lls, 
timulating them for T cell independent (type 1) responses.  It is a potent stimulator of B 
vitro, and has been found to be possibly helpful in lentiviral-based gene therapy.  
PS, or lipopolysaccharide, is a component of the cell wall of gram-negative bacteria.  It 
 an inducer of T cell independent type 1 responses and has adjuvant effects.  LPS acts 
a




Also known as CD154, CD40L is a molecule on T cells that interacts with the molecule 
CD40 on B cells during a T cell dependent immune response.  CD40L drives B cells into 
the cell cycle, causing them to proliferate both in vivo and in vitro
r
IL-10, and IL-12 to 
 
CpG 
Short, single-stranded, unmethylated bacterial DNA.  CpG binds to TLR9 on B ce
s
cells in 





  61 
through binding to LPS-binding protein and TLR4 on B cells.  In this experiment, LPS 
context of IL-4 to stimulate the B cells.  (1) 
molecules of any class, and is typically 
itogenic for the B cells.  It is used to study T cell independent type 2 responses.  In this 
t, anti-IgA and anti-IgG were used in the context of IL-2, IL-4, IL-10, and 
timulate the cells.  (1) 
 cell growth and J-chain synthesis. (1) 
 
was used in the 
 
Anti-Ig (α-Ig) 
An antibody to the B cell receptor (BCR) that causes the BCR to cross-link, activating the 






Interleukin-2, or IL-2, is the cytokine that is most central to an adaptive immune 
response.  IL-2 is secreted by naïve T cells, TH1 cells, and some CD8+ T cells, and drives 
T cell development.  In B cells, IL-2 stimulates
 
IL-4 
Interleukin-4, or IL-4, is a cytokine secreted by TH2 T cells.  In a T cell-B cell interaction, 
it is focused at the site of contact between the T cell and the B cell.  IL-4 activates B cells, 
induces growth and class switch (predominantly to IgG1 and IgE), and increases 
expression of MHC Class II molecules.  (1) 
 
IL-10
Interleukin-10, or IL-10, is a cytokine secreted by TH2 cells.  It increases MHC Class II 
expression and aids in activating B cells for a T cell dependent response. (1) 
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IL-12 
Interleukin-12, or IL-12, is a cytokine that is naturally produced by macrophages in 
esponse to antigenic stimulation.  IL-12 typically stimulates TH0 differentiation to TH1 
 NK cell development.  It has also been shown to have a role in 
e cell surface.  IL-15 induces the proliferation of T cells 
s well as normal and malignant B cells.  It has been connected to multiple myeloma.  (1, 
treptavidin is a tetrameric protein that binds very tightly to biotin.  It is frequently used 
biotinylated antibodies using a conjugated fluorescent or enzymatic protein. (34) 
monly used dye for 
ACS and confocal microscopy.  The optimal excitation 
gth for FITC is 495 nm, and it emits light at 519 nm, in 
r
cells, as well as
autoimmunity and allergic disease.  (1) 
 
IL-15 
Interleukin-15, or IL-15, is a cytokine that is similar in properties to IL-2, but utilizes a 










Fluorescein Isothiocyanate, or FITC, is a small, organic, 
fluorescent molecule that is the most com
F
wavelen
the green light range.  Interestingly, fluorescein is also the dye 
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used commonly in eye exams, and is also used to dye the Chicago River green every St. 
PI, is a 
uorescent stain that binds to DNA.  DAPI 
passes through the cell membrane, 
) 
or PE, is a large, fluorescent protein that is 
avelength is 578 nm, creating an extremely bright orange-
or.  (1, 29). 
 
he β subunit of cholera 
toxin, which binds tightly to GM1.  (5,8) 
Patrick’s Day.  (1, 29, 30) 
 
DAPI 
4’, 6-diamidino-2-phenylindole, or DA
fl
easily 
making it effective for staining the nucleus of 
live and fixed cells.  The optimal excitation wavelength for DAPI bound to DNA is 358 





commonly used for FACS and confocal microscopy.  Its 






































Cell Surface Markers: 
GM1 
GM1 is a ganglioside that is highly enriched in lipid raft portion
It is typically used to mark lipid rafts in lymphocytes, using t
s of the cell membrane. 
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CD162 
P-selectin glycoprotein ligand-1 (PSGL-1), or CD 162, is a cell surface molecule that is 
xpressed constitutively on leukocytes.  It is commonly used as a marker of the trailing 
r uropod, of the cell, as it migrates to the trailing edge in a polarized lymphocyte.  






Leukocyte Function Antigen-1 (LFA-1), or CD11a
molecule, found on the surface of leukocytes.  LFA-1 interacts with ICAM-1 and ICAM-3 
to mediate interactions between T cells and B cells.  Due to its cell adhesion functions, 
LFA-1 i
/CD18, is a β2 integrin, or cell adhesion 
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Section XV: Experimental Materials and Methods 
 
ble cells were counted using a Beckman-Coulter cell counter.  These cells were 
orted using MACS, using CD19+ selection for B cells.  The cells were then washed using 
 media and resuspended at a concentration of 1 x 106 cells/100 µL in 
plate.  The cells were either left unstimulated or stimulated with CD40L + IL-2, IL-4, IL-
10, and IL-12; CpG + IL-15; LPS + IL-4; or anti-IgA and IgG + IL-2, IL-4, IL-10, and IL-
12.  The cells were incubated for several days at 37°C and removed at various time 




Once removed from the 48 well plate, the cells were washed and resuspended in FACS 
buffer.  The cells were then stained using monoclonal antibodies (mAb) or ligands to 
one or more of: TACI, CD162, CD11a, and GM-1.  Secondary antibodies, conjugated to 
FITC or PE, were added when necessary.  Control antibodies were used that were 
appropriate for the molecule being stained for.  Cells were incubated with the antibodies 
in a dark room at 4°C and washed in between incubations with FACS buffer.  Following 
Isolation of B Cells 
Normal human peripheral blood mononuclear cells (PBMC) were isolated from a buffy 






Cell Culture and Stimulation 
Previously sorted CD19+ B cells were cultured in RPMI complete media in a 48 well 
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fluorescent staining and washing, cells were resuspended in 1% paraformaldehyde 
r microscopy. (PFA) to fix the cells fo
 
Please Note: Throughout the course of the experiment, many other molecules were 
tested briefly as markers of polarization for human B cells.  The molecules listed above 
were found to be the most effective markers, and therefore, other molecules used and 




Once stained for fluorescent microscopy, the cells were mounted on a 10-well 
microscope slide.  Vectashield DAPI stain was added to the cells and the slide was 
covered with a cover slip.  The cells were examined by confocal microscopy using a Zeiss 
LSM 510 inverted confocal microscope.  All images were taken on one or more color 
channel at a resolution of 300X. 
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Section XVI: Experimental Results 
TACI is Differentially Localized i
 
n CpG-Stimulated B Cells 
Following the stimulation of CD19+ PBMC and incubation for several days, the 
It was initially 
und that while TACI 
xhibits a capping of 
TACI at one end of the 
cell (Fig. 1).  The 
capping effect was 
evident by day 3 of the 
experiment and grew more pronounced by the fifth day following stimulation.  This 
effect occurs in approximately 10% of TACI-positive cells under CpG stimulation, while 
it was observed in only 1% of TACI-positive CD40L-stimulated B cells. 
cells were stained and 
analyzed to determine 
the localization of TACI 
on the cell surface. 
fo
is uniformly distributed 
on the surface of B cells 
that are untreated or 
are stimulated with 
CD40L, a subset of 




Fig. 1 TACI is differentially localized in CpG-stimulated B cells.  (A) In B 
cells stimulated with CpG, but not with CD40L, TACI localizes at one end of 
the cell.  The capping phenotype appears around day 3 and becomes more 
drastic by day 5 following stimulation.  (B) Cells stimulated with LPS and anti-
Ig Ab do not exhibit TACI capping. 
  68 
Following the initial observations that TACI is differentially localized on CpG-
h was expanded to 
includ
 
n was not observed with either LPS or α-Ig, and with both 
uniformly distributed around the cell surface.  These results 
apping is not common to all TI responses, but do not necessarily 
indicat ly stimulus that causes this phenomenon. 
ze the localization of TACI, a colocalization experiment was 
f CI was associating with lipid rafts under any of the stimuli 
ssociated (6).  In unstimulated B cells, TACI and GM1 
ibuted throughout the cell surface, showing little to no 
e pattern is repeated for CD40L, LPS, and α-Ig.  Under CpG 
h TACI and GM1 exhibit capping on one end of the cell, and a 
localization is observed (Fig. 2).  These results indicate that 
ation of TACI was compared to the localization of known leading edge and trailing 
stimulated B cells but not on CD40L-stimulated cells, the researc
e additional stimuli.  To determine if the capping phenomenon was common to all 
TI stimuli, LPS was adde
The capping phenomeno
stimuli TACI remained 
suggest that TACI c
d as a TI-I stimulus, and α-Ig was added as a TI-II stimulus. 
e that CpG is the on
 
TACI Colocalizes with Lipid Rafts Following CpG Stimulation 
To further characteri
carried out to determine i
studied.  Colocalization w
known to be constitutively raft-a
are both uniformly distr
colocalization.  This sam
stimulation, however, bot
significant amount of co
upon CpG stimulation, TAC
 
TACI Does Not Colocalize with Trailing Edge Marker CD162 Following CpG 
Stimulation 
As the cells that exhibited TACI capping had a polarized appearance, the 
localiz
 TA
ith lipid rafts was examined using the marker GM1, which is 
I localizes to the lipid raft portion of the cell surface. 
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edge 
TACI was first 
under 
significant effect on 




lymphocytes.  CD162 
(also known as PSGL-
1) is a known marker 
of the trailing edge in 
both B cells and T 
cells, and therefore 
compared to CD162 
both CD40L 
and CpG stimulation 
(7, 9).  LPS and α-Ig 
were omitted from 
this experiment, as 
they failed to cause 
the polarized 
phenotype and 
seemed to have no 
Fig. 2 TACI colocalizes with lipid rafts following CpG stimulation.  (A) In 
calize 
TACI 
colocalizes with GM1 and the cells exhibit a polarized morphology. 
B cells stimulated with CD40L, LPS, and anti-Ig Ab, TACI does not colo





venly distributed throughout the cell surface, exhibiting little to no colocalization.  
In contrast, following CpG stimulation, TACI and CD162 both exhibited differential 
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localization in a subset of 
(Fig. 3).  T
to the trailing edge of 
the polarized, CpG-
stimulated B cells. 
These results were 
echoed by staining 
with trailing edge 
markers CD43 and 
CD44 (33; preliminary 











cells, with each molecule moving to an opposite side of the cell 






Fig. 3 TACI does not colocalize with uropod marker CD162 following 
timulation.  (A) In fresh, unstimulated B cells and cells stimulated with 
CD40L, TACI does not colocalize with CD162, and both molecules are evenly 
CpG s
distributed around the cell surface. (B) In cells stimulated with CpG, TACI and 
CD162 exhibit opposite polarized localization. 
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TACI Colocalizes with Leading Edge Marker CD11a in CpG-Stimulated B 
Cells 
In order to 
confirm the results o
the CD162 
colocalization staining, 
TACI localization was 
compared to the 
localization of CD11a 
(also known as LFA-1), 





).  In a similar 
anner to the other colocalization assays, in unstimulated and CD40L-stimulated B 
ells, TACI and CD11a showed no significant colocalization, with both molecules being 
niformly distributed aro  the cell.  In CpG-stimulated cells, however, TACI and 
D11a both localized to th  
mounts of colocalizati  
D162 and TACI, suggest that upon CpG stimulation, TACI migrates to the leading edge 
f the polarized B cell. 
 
Fig. 4 TACI colocalizes with leading edge marker CD11a following CpG 
stimulation.  In cells stimulated with CD40L, TACI and CD11a are evenly 
distributed throughout the cell surface on day 5 following stimulation.  In cells 





C e same compartment of the cell surface, exhibiting significant
(Fig. 4).  These results, along with the results of staining fora on 
C
o
  72 
Section XVII: Discussion and Conclusion 
 
In preliminary data before the summer’s experiments were carried out, it was 
noted that when APRIL is adde
ect as it does on CD40L-stimulated cells.  This data was the 
bed in this thesis, but these experiments are only 
 the possible mechanism of this difference in APRIL function. 
is long process was the imaging of TACI localization under 
.  It was determined that TACI “caps,” or localizes at one 
 3 in B cells under CpG stimulation but not under CD40L 
CpG stimulation vs. less than 1% under CD40L stimulation).  
 to this intriguing data, including the discovery that TACI does 
ls following LPS or anti-Ig Ab stimulation.  These results 
 
nt.  Although no further stimuli were tested during the 
 rafts have been shown to cluster upon cell stimulation, it was 
important to determine whether TACI capping upon CpG stimulation was related to 
lipid rafts in any way.  Through the summer’s experiments, it was shown that TACI 
colocalizes with lipid rafts as both cluster at one end of the cell following CpG 
d to CpG-stimulated B cells, the APRIL does not have the 
same antiproliferative eff
inspiration for the experiments descri
the first step to discerning
The first task in th
CD40L and CpG stimulation
end of the cell, upon day
stimulation (10% under 
Further detail was added
not display capping in B cel
indicate that the capping p
dependent or T cell indep
summer’s experiments, preliminary data from the lab later in the year suggests that the 
capping phenomenon may not be exclusive to CpG stimulation.  Perhaps the CpG 
stimulation pathway, acting through TLR9, is the key to TACI capping.  In order to 
determine this, we must first determine why TACI may be capping, and how this relates 
to the lack of APRIL function in CpG-stimulated B cells. 
Because lipid rafts are a newly discovered feature of the cell surface of 
lymphocytes, and lipid
henomenon is not based upon whether the response is T cell
ende
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response to a stimulus in order 
to mou
iately following lipid raft clustering or if TACI is recruited to the lipid raft 
following raft clustering.  This would be an interesting topic for further experiments. 
To further characterize the localization of TACI in CpG-stimulated B cells, TACI 
localization was compared to that of trailing edge marker CD162 and leading edge 
marker CD11a.  Because of the polarized morphology of the CpG-stimulated B cells, and
alization of TACI to the smaller end of the cell, it was expected that TACI was 
migrating to the uropod, or trailing edge, of the cell following stimulation.  Upon 
comparing TACI localization to that of CD162 and CD11a, however, it is evident that 
TACI is localizing to the leading edge of CpG-stimulated, polarized B cells. 
This summer’s experiments have shown that upon CpG stimulation, and not 
CD40L stimulation or stimulation with other TI stimuli, TACI clusters at one end of the 
cell surface.  Furthermore, TACI colocalizes with lipid rafts in the leading edge 
compartment of the cell membrane.  These findings present the intriguing questions of 
why this clustering occurs, and why TACI may be drawn to the lipid raft portion and 
leading edge of the cell.  While much about receptor clustering, lipid rafts, and cell 
polarization remains unknown, a few ideas come to mind that may help explain the 
results of these experiments. 
Typically, receptors cluster on the cell surface in 
nt an effective, or stronger, response to the specific stimulus.  Additionally, lipid 
rafts are commonly thought of as signaling platforms for clustered receptors, as many of 
the molecules that cluster in lipid rafts are instrumental in activating signaling 
pathways.  The B cell receptor is one example of a receptor which clusters in lipid rafts, 
as the BCR must crosslink in order for cell signaling and antigen uptake to occur.  In this 
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model of receptor clustering, the idea is that receptors cluster and become associated 
with lipid rafts in order to increase the efficiency of cell signaling.  This presents an 
interesting dilemma in the case of TACI, however.  In the results that led to this 
summ
y this model, 
TACI c
erns characteristic of the leading edge may provide a hint 
as to th
er’s experiments, the CpG-stimulated cells, in which TACI forms clusters, were 
not as strongly affected (or affected at all) by APRIL binding to TACI on the cell surface.  
It is, perhaps, possible that APRIL has a different function in these cells, and that in this 
case TACI is carrying out some form of signaling but does not negatively regulate cell 
proliferation.  An alternative to this explanation is the model proposed by Kwang-Il Lim 
and John Yin, who suggest that in some cases, receptor clustering and localization in 
lipid rafts can inhibit signal transduction rather than activating it.  (35)  B
lustering upon CpG stimulation would be a way for the cell to stop TACI from 
negatively regulation proliferation.  Only time will tell if either of these two 
explanations, or another explanation, can fully discern the reasons for TACI clustering 
upon CpG stimulation. 
Further complicating the dilemma of TACI clustering is the data suggesting that 
TACI migrates to lipid rafts in the leading edge of the polarized, CpG-stimulated B cells.  
As much remains to be learned about cell polarization, no concrete answers can be 
found from this data, but patt
e reasons for TACI clustering in the leading edge of the cell.  The leading edge of 
a polarized lymphocyte is commonly associated with the recognition of chemokines and 
other signaling molecules, as well as substrate adhesion and intercellular adhesion, 
particularly migration into tissues and B cell-T cell interactions.  As with lipid rafts, it is 
interesting that TACI migrates to a compartment of the cell in which it is expected to 
have heightened signaling, while TACI signaling appears to be ineffective in instances in 
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which TACI clusters.  It is also interesting that the leading edge is thought to be 
instrumental in B cell interactions with T cells, while TACI migrates to the leading edge 
in response to a T cell independent stimulus.  The current profile of a polarized 
lymphocyte offers many possibilities for TACI function in the leading edge, and 
additionally it is possible that TACI migrates to the leading edge as a result of being 
excluded from the trailing edge of the cell.  It is also important to remember that much 
of the research on cell polarization has been carried out on T cells, and therefore 
questions which are considered answered in T cells may in fact turn out differently in B 
cells.  As more experimentation is carried out in B cells, and cell polarization and TACI 
localization are examined more carefully, some of these questions may eventually be 
answered. 
While the summer’s experiments brought about many answers, they also created 
many more questions.  First among these is the discrepancy in markers for cell surface 
compartments.  In B cells as well as T cells, ganglioside GM1 is used as a marker of lipid 
rafts on the cell surface.  In T cells, it is commonly associated with uropod rafts, but no 
literature exists describing the localization of GM1 in polarized B cells. (36, 37)  
Interestingly, in the experiments described in this thesis, TACI has been found to 
colocalize with leading edge marker CD11a, as well as GM1, in polarized B cells.  This 
data lends the suggestion that perhaps in B cells, GM1 is located in lipid rafts in the 
leading edge, not the uropod.  More experimentation and analysis are needed in order to 
confirm this suggestion; however it is most definitely an interesting possibility. 
Next among the questions raised is the question of the function of TACI 
clustering.  No experiments were carried out to tie the clustering of TACI back to the 
initial observation that CpG-stimulated B cells do not respond to APRIL in the same way 
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as cells under other stimuli.  In order for the data described in this thesis to be useful, 
this connection needs to be examined in order to determine the clinical relevance of 
these findings.  A further experiment along this line would be a confocal assay for APRIL 
binding to the stimulated B cells.  One very interesting possibility raised by the data in 
these experiments is that APRIL binding to TACI utilizes another APRIL binding 
partner, heparan sulfate proteoglycans, to strengthen the binding reaction with TACI; in 
this case, TACI clustering may isolate TACI from the heparan sulfate proteoglycans, 
making APRIL binding ineffective.  Determining the location and extent of APRIL 
binding in the polarized B cells would help to bolster or eliminate this possibility and 
perhaps elucidate the role of TACI clustering in B cell response to APRIL. 
Still other questions remain in regards to the TACI clustering dilemma.  Although 
no clustering was found with CD40L, LPS, or anti-Ig Ab, one must wonder whether 
TACI clusters only in response to CpG, or if other stimuli may also have the same effect.  
If other stimuli also cause TACI to cluster, it becomes necessary to determine if the lack 
of response to APRIL is also coupled to these stimuli, or if TACI clustering may be 
unrelated to the APRIL response (or lack thereof).  Additionally, commonalities may 
need to be determined between stimuli that cause TACI to cluster, in order to discover 
the mechanism or logic behind the clustering phenomenon. 
All of the questions listed above, as well as many others, still remain to be 
explored.  Because of the importance of APRIL and TACI to B cell research, these topics 
will certainly be more fully analyzed in the years to come. 
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Section XVIII: Further Reading 
In the months following the experiments outlined in this thesis, much research 
has taken place to further elucidate the role of TACI in B cell function.  Recent 
developments include the discovery of another binding partner for TACI, syndecan-2, 
and the connection of TACI to new disorders, including rheumatoid arthritis and 
Waldenström macroglobulinemia. While it is beyond the scope of this paper to describe 
each new discovery in detail, a list of the pertinent recent scientific literature follows. 
 
Further Reading: 




production and malignant B-cell growth in Waldenström macroglobulinemia.  Blood.  
Relates patterns of BLyS overexpression and expression of BCMA, BAFF-R, and TACI to patients 
with Waldenström macroglobulinemia. 
 
Fu L, et al.  2006.  Constitutive NF-κB and NFAT Activation Leads to Stimulation of the 
Blood.  First Edition Paper. 
 Describes the activation of the BLyS survival pathway in B cells in individuals with lymphomas. 
 
Describes the discovery of a new binding partner for TACI, syndecan-2, and the activation of 
TACI by syndecan-2. 
 
Elsawa SF, et al.  2006.  B-lymphocyte stimulator (BLyS) stimulates immunoglobulin 
107:2882-2888. 
BLyS Survival Pathway in Aggressive B Cell Lymphomas.  
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Diaz-de-Durana Y, et al.  2006.  TACI-BLyS signaling via B-cell-dendritic cell 
cooper
 
munodeficiency.  Curr Opin Allergy Clin Immunol.  6:496-503. 
Describes the discovery of genetic defects in TACI and BAFF-R in patients with common variable 
immunodeficiency (CVID); elaborates on possible roles for TACI in B cell biology. 
J. Clin. Invest.  
115:3083-3092. 
 Relates TACI expression to a pattern of diffuse synovitis in patients with rheumatoid arthritis. 
 
Zheng Y, et al.  2005.  A role for B cell-activating factor of the TNF family in chemically 
induced autoimmunity.  J. Immunol.  175:6163-6168. 
Describes the phenomenon of Hg-induced autoimmune syndrome, as well as the role of BLyS in 
mediating this autoimmunity.  TACI-Ig inhibits Hg-induced autoantibody production. 
ation is required for naive CD8+ T-cell priming in vivo.  Blood.  107:594-601. 
Suggests the necessity of interactions between B cells and DCs via TACI and BLyS for the 
generation of adequate numbers of APCs to prime naïve CD8 T cells for CTL response. 
Salzer U, Grimbacher B.  2005.  TACItly changing tunes: farewell to a yin and yang of 
BAFF receptor and TACI in humoral immunity?  New genetic defects in common 
variable im
 
Seyler TM, et al.  2005.  BLyS and APRIL in rheumatoid arthritis.  
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Closing Comments 
Through all of the work I have done on my thesis this year, I have learned qu
 
ite a 
bit.  In eaving 
all of t my basic 
ound in immunology, immensely.  I have 
built upon my understanding of the BLyS/APRIL system and TACI in B cells, and I have 
 
field of biology. 
Most importantly, writing a thesis has been a process of self-discovery.  What I 
pathway to what I hope will be a long and satisfying career.  Perhaps my interests will 
hange
ave studied, but after spending a year intensively researching and learning about 
 
o handle the rigors of 
a gradu
with the 
knowledge that regardless of what happens, something substantial has already come of 
my education here.  I have certainly gained much during my four years here, and in 
particular I have developed the knowledge and discipline necessary to write something 
this long.  It is my hope that as a reader, you have enjoyed this journey as much as I 
have. 
 addition to learning about the importance of having a work ethic and not l
he work for a large project until the last minute, I have strengthened 
knowledge of biology, as well as my backgr
come to grasp the reasons and basic research behind my summer research project.  I 
have also discovered much about the extensive complexity and interrelatedness of the
have written about in this paper is not just a summer research project anymore; it is a 
c  slightly and I will move away from B cell biology or from the specific systems I 
h
immunology, I know that it will be a lifelong passion.  I have also discovered that I am
capable of intensive, self-directed research, and that I will be able t
ate education in immunology. 
As I finish this thesis, I finish my final year at Boston College, secure 
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Janeway, Charles A.; Travers, Paul; Walport, Mark; Shlomchik, Mark J.  
Garland Science Publishing, 2005. 
Jelinek, Diane F. & Darce, Jaime R. “Human B Lymphocyte Malignancies: Exploitation 
vol. 8, pp. 266-288. 
Sompayrac, Lauren.  How the Immune System Works, 2nd Edition.  Oxford: Blackwell 
ell, Neil A. & Reece, Jane B.  Biology, Sixth Edition.  San Francisco: Benjamin 
 
Immunobiology: the immune system in health and disease, 6th Edition.  New York: 
 
of BLyS and APRIL and Their Receptors.”  Current Directions in Autoimmunity, 2005, 
 
Science, 2003. 
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